Isarna Therapeutics Announces First Patient Enrolled in International Phase IIa Clinical Study in Ophthalmology Indications Wet AMD and DME

Isarna Therapeutics announced the enrollment of the first patient in the BETTER Study, a parallel, two-segment Phase IIa clinical study to evaluate Isarna’s lead candidate ISTH0036 in patients with wet age-related macular degeneration (AMD) and diabetic macular edema (DME).